According to filings with the U.S. Securities and Exchange Commission, Athos Therapeutics is raising up to $34,999,995.00 in new funding. Sources indicate that as part of senior management President, Dimitrios Iliopoulos played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Athos Therapeutics
Developing precision therapeutics for patients with chronic inflammatory diseases incorporating artificial intelligence and machine learning algorithms. Athos Therapeutics Inc. is a late pre-clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel, other Autoimmune Diseases, and cancer. Athos has developed a unique platform able to identify and develop novel drugs for patients with autoimmune and chronic inflammatory diseases. This approach is based on the integration of medicinal chemistry and systems biology through machine learning.

To learn more about Athos Therapeutics, visit http://athostx.com/

Contact:
Dimitrios Iliopoulos, President
857-222-0410
https://www.linkedin.com/in/dimitriosiliopoulos/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.